Establishing bioequivalence for inhaled drugs; weighing the evidence
- 24 June 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 8 (10) , 1297-1308
Abstract
During drug development and product life-cycle management, it may be necessary to establish bioequivalence between two pharmaceutical products. Methodologies to determine bioequivalence are well established for oral, systemically acting formulations. However, for inhaled drugs, there is currently no universally adopted methodology, and regulatory guidance in this area has been subject to debate. This paper covers the current status of regulatory guidance on establishing the bioequivalence of topically acting, orally inhaled drugs, the value and limitations of in vitro and in vivo bioequivalence testing, and the practical issues associated with various approaches. The reader will gain an understanding of the issues pertaining to bioequivalence testing of orally inhaled drugs, and the current status of regulatory approaches to establishing bioequivalence in different regions. Establishing bioequivalence of inhaled drug products involves a multistep process; however, methodologies for each step have yet to be fully validated. Our lack of understanding about the relationship between in vitro, in vivo and clinical data suggests that in most cases, unless there is a high degree of pharmaceutical equivalence between the test and reference products, consideration of a combination of preclinical and clinical data may be preferable to abridged approaches relying on in vitro data alone.Keywords
This publication has 29 references indexed in Scilit:
- Role of Pharmacokinetics in Establishing Bioequivalence for Orally Inhaled Drug Products: Workshop Summary ReportJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2011
- Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacerBritish Journal of Clinical Pharmacology, 2010
- In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung DiseasesThe AAPS Journal, 2009
- Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: Implications for establishing bioequivalence of inhaled productsClinical Therapeutics, 2009
- Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalersCurrent Medical Research and Opinion, 2008
- In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A reviewAAPS PharmSciTech, 2007
- Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic methodBritish Journal of Clinical Pharmacology, 2004
- Particle Deposition in a Cast of Human Oral AirwaysAerosol Science and Technology, 1999
- Standards for Bioequivalence of Inhaled ProductsClinical Pharmacokinetics, 1994
- Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung.Thorax, 1993